CY1111884T1 - Μονοκλωνικο αντισωμα αντι-met, θραυσματα και κομιστες αυτου, για την αγωγη νεοπλασιων και αντιστοιχα προϊοντα - Google Patents
Μονοκλωνικο αντισωμα αντι-met, θραυσματα και κομιστες αυτου, για την αγωγη νεοπλασιων και αντιστοιχα προϊονταInfo
- Publication number
- CY1111884T1 CY1111884T1 CY20111100926T CY111100926T CY1111884T1 CY 1111884 T1 CY1111884 T1 CY 1111884T1 CY 20111100926 T CY20111100926 T CY 20111100926T CY 111100926 T CY111100926 T CY 111100926T CY 1111884 T1 CY1111884 T1 CY 1111884T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- monoclonal antibody
- monoclonic
- cottages
- fragrances
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Abstract
Αποκαλύπτεται η χρήση μονοκλωνικού αντισώματος κατευθυνόμενου έναντι της εξωκυτταρικής επικράτειας του αυξητικού παράγοντα ηπατοκυττάρων για την παρασκευή φαρμάκου για την αγωγή νεοπλασιών και/ή μεταστάσεων και διαγνωστικού εργαλείου για την ανίχνευση νεοπλαστικών κυττάρων καθώς και κομιστών περιλαμβανόντων τουλάχιστον κάποιο τμήμα της νουκλεοτιδοαλληλουχίας που κωδικεύει το μονοκλωνικό αντίσωμα αντι-Met, προϊόντα περιέχοντα το μονοκλωνικό αντίσωμα αντι-Met και/ή τουλάχιστον ένα θραύσμα αυτού και τουλάχιστον έναν αναστολέα κινάσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06101345 | 2006-02-06 | ||
EP07704350A EP1981981B1 (en) | 2006-02-06 | 2007-02-05 | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111884T1 true CY1111884T1 (el) | 2015-11-04 |
Family
ID=36616994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100926T CY1111884T1 (el) | 2006-02-06 | 2011-09-26 | Μονοκλωνικο αντισωμα αντι-met, θραυσματα και κομιστες αυτου, για την αγωγη νεοπλασιων και αντιστοιχα προϊοντα |
Country Status (21)
Country | Link |
---|---|
US (2) | US8388958B2 (el) |
EP (2) | EP1981981B1 (el) |
JP (1) | JP5306828B2 (el) |
KR (1) | KR101429297B1 (el) |
CN (1) | CN101379192B (el) |
AT (1) | ATE514715T1 (el) |
AU (1) | AU2007213804B2 (el) |
BR (1) | BRPI0707480A8 (el) |
CA (1) | CA2638889C (el) |
CY (1) | CY1111884T1 (el) |
DK (1) | DK1981981T3 (el) |
EA (1) | EA015580B1 (el) |
ES (1) | ES2368864T3 (el) |
IL (1) | IL192879A (el) |
MX (1) | MX2008009833A (el) |
PL (1) | PL1981981T3 (el) |
PT (1) | PT1981981E (el) |
SG (2) | SG169382A1 (el) |
SI (1) | SI1981981T1 (el) |
WO (1) | WO2007090807A1 (el) |
ZA (1) | ZA200806559B (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
IL198545A0 (en) | 2008-05-14 | 2011-07-31 | Metheresis Translational Res Sa | High affinity binding site of hgfr and methods for identification of antagonists thereof |
EP2127683A1 (en) * | 2008-05-29 | 2009-12-02 | Metheresis Translational Research SA | Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits |
PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
KR101671378B1 (ko) | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
KR101748707B1 (ko) | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | c-Met에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
AU2011226103C1 (en) | 2010-03-10 | 2016-04-28 | Genmab A/S | Monoclonal antibodies against c-Met |
WO2011125458A1 (ja) | 2010-04-02 | 2011-10-13 | 富士レビオ株式会社 | 抗癌剤の効果の診断用マーカー |
WO2011150454A1 (en) * | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
WO2012030842A2 (en) * | 2010-09-03 | 2012-03-08 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
US8637027B2 (en) | 2010-11-03 | 2014-01-28 | Argen-X B.V. | Anti c-Met antibodies |
EP2500036B1 (en) * | 2011-03-18 | 2014-05-07 | Metheresis Translational Research SA | MET inhibitors for enhancing radiotherapy efficacy |
JP2014530201A (ja) | 2011-09-20 | 2014-11-17 | イーライ リリー アンド カンパニー | 抗c−Met抗体 |
EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
RU2014124842A (ru) | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | Очистка анти-с-мет антител |
US20150147274A1 (en) * | 2011-12-02 | 2015-05-28 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
CN103382223B (zh) * | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
EP2863946A4 (en) * | 2012-06-21 | 2016-04-13 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET |
ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
WO2016149116A1 (en) * | 2015-03-13 | 2016-09-22 | University Of Maryland, Baltimore | Antibodies targeting s100b and methods of use |
CN113150147A (zh) | 2015-03-16 | 2021-07-23 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
US11299547B2 (en) * | 2016-09-29 | 2022-04-12 | Mitsubishi Tanabe Pharma Corporation | CMET monoclonal binding agents, drug conjugates thereof and uses thereof |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
CN106872695B (zh) * | 2017-01-20 | 2019-06-11 | 中山大学 | 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒 |
IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
IT201800003875A1 (it) * | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
US20210163604A1 (en) * | 2018-03-28 | 2021-06-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
IT201800009282A1 (it) | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US6814962B1 (en) | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
-
2007
- 2007-02-05 SI SI200730720T patent/SI1981981T1/sl unknown
- 2007-02-05 MX MX2008009833A patent/MX2008009833A/es active IP Right Grant
- 2007-02-05 EA EA200870234A patent/EA015580B1/ru not_active IP Right Cessation
- 2007-02-05 CN CN2007800047097A patent/CN101379192B/zh active Active
- 2007-02-05 WO PCT/EP2007/051066 patent/WO2007090807A1/en active Application Filing
- 2007-02-05 AU AU2007213804A patent/AU2007213804B2/en active Active
- 2007-02-05 KR KR1020087016543A patent/KR101429297B1/ko active IP Right Grant
- 2007-02-05 BR BRPI0707480A patent/BRPI0707480A8/pt not_active Application Discontinuation
- 2007-02-05 CA CA2638889A patent/CA2638889C/en active Active
- 2007-02-05 SG SG201100805-9A patent/SG169382A1/en unknown
- 2007-02-05 EP EP07704350A patent/EP1981981B1/en active Active
- 2007-02-05 ES ES07704350T patent/ES2368864T3/es active Active
- 2007-02-05 EP EP10151809A patent/EP2192188A1/en not_active Withdrawn
- 2007-02-05 PL PL07704350T patent/PL1981981T3/pl unknown
- 2007-02-05 SG SG201100806-7A patent/SG169383A1/en unknown
- 2007-02-05 AT AT07704350T patent/ATE514715T1/de active
- 2007-02-05 US US12/223,623 patent/US8388958B2/en active Active
- 2007-02-05 DK DK07704350.3T patent/DK1981981T3/da active
- 2007-02-05 PT PT07704350T patent/PT1981981E/pt unknown
- 2007-02-05 JP JP2008553739A patent/JP5306828B2/ja active Active
-
2008
- 2008-07-17 IL IL192879A patent/IL192879A/en active IP Right Grant
- 2008-07-28 ZA ZA2008/06559A patent/ZA200806559B/en unknown
-
2011
- 2011-09-26 CY CY20111100926T patent/CY1111884T1/el unknown
- 2011-11-04 US US13/373,101 patent/US8729043B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111884T1 (el) | Μονοκλωνικο αντισωμα αντι-met, θραυσματα και κομιστες αυτου, για την αγωγη νεοπλασιων και αντιστοιχα προϊοντα | |
CY1121162T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
CY2017013I2 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
NL301089I2 (nl) | imlifidase | |
CY1118369T1 (el) | Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος | |
ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
CY2014028I1 (el) | Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης | |
ATE527253T1 (de) | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer | |
CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CY1115571T1 (el) | Νεες ενωσεις και μεθοδοι για θεραπεια | |
HN2009003002A (es) | Compuestos de piridopirimidinonas inhibidores de pi3k-alfa | |
CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
BRPI0518794A2 (pt) | composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial | |
DE60315135D1 (de) | Therapiesonde | |
ATE499370T1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen | |
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
CY1124281T1 (el) | Θεραπευτικη χρηση ειδικου προσδετη σε σχετικες me msrv ασθενειες | |
DK1847524T3 (da) | Terphenylderivater til behandling af Alzheimers sygdom | |
CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
CY2018006I2 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
SE0301650D0 (sv) | Novel compounds |